Joint Pain Injections Market Analysis

Joint Pain Injections Market Analysis

To get key market trends

  Download Free Sample

Based on injection type, the joint pain injections market is segmented as hyaluronic acid injection, corticosteroid injection and platelet rich plasma injection. the hyaluronic acid injection segment held a dominant market share in 2022. Furthermore, human joints are constantly subjected to wear and tear, hyaluronic acid, like synovial fluid, has excellent lubricating and shock-absorbing properties that help to reduce joint stiffness and discomfort. The anti-inflammatory properties of hyaluronic acid and ability to provide short-term relief in joint sprains suffered by athletes and industrial workers, corticosteroid injections are used as an adjuvant drug in joint pain. Thus, rising demand for hyaluronic acid injections would drive the overall market statistics.
 

Based on joint type, the joint pain injections market is segmented as knee, shoulder & elbow, and ankle & hip. The knee segment held a dominated the market in 2022, whereas the hip joint segment is expected to grow with a highest CAGR, owing to the rise in the number of accidents and injuries related to the accidents leading to the hip joint pain and rise in the number of geriatric patients.
 

Based on end-use the Joint Pain Injections market is segmented as hospitals, clinics, and others. The hospitals segment is estimated to show a lucrative CAGR of over 8.9% through 2032. This high segmental share is attributed to availability of wide varieties of injections in the hospitals or in hospitals pharmacies. Strong end-uses and extensive network of suppliers to hospitals assists to reach a wide customer base and manage consumer compliance. Segment expansion is due to huge need for hospitalization by people with orthopedic diseases.
 

U.S. Joint Pain Injections Market is anticipated to reach more than USD 4 billion by 2032. The significant market share is owing to several factors including presence of major market players, and the high prevalence of musculoskeletal problems that cause joint aches. Public awareness of non-invasive orthopaedic therapies has grown, as has implant technology innovation and sophisticated healthcare facilities.
 

According to the Centres for Disease Control and Prevention, chronic pain caused by arthritis affects millions of people in the United States each year. Arthritis affects one out of every four people, and 15 million people report significant joint pain because of it. One of the factors driving the regional market statistics. Furthermore, major market competitors are heavily investing in research, which will benefit the North American industry.